Alignment Healthcare (NASDAQ: ALHC) CEO reports stock sales

Rhea-AI Filing Summary

Alignment Healthcare CEO share transactions: Shares associated with Chief Executive Officer and director John E. Kao, held indirectly through the JEK Trust for which he serves as trustee, were sold in two transactions on 01/12/2026 under a Rule 10b5-1 trading plan adopted on 03/12/2025. The trust sold 177,273 shares of common stock at a weighted-average price of $21.0997 per share and an additional 2,727 shares at a weighted-average price of $21.5665 per share, with individual trades occurring within the disclosed price ranges.

Following these sales, indirect holdings reported as held by the JEK Trust totaled 2,832,641 shares, and direct holdings reported in John Kao’s name totaled 1,568,379 shares of Alignment Healthcare common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE CA 92868

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		S(1)		177,273	D	$21.0997(2)	2,835,368(3)	I	See Footnote(4)
Common Stock	01/12/2026		S(1)		2,727	D	$21.5665(5)	2,832,641(3)	I	See Footnote(4)
Common Stock								1,568,379(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 03/12/2025

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.48 to $21.47. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Balances in column 5 reflect the transfer on 01/08/2026 of 665,915 shares held directly by Mr. Kao to the JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

4. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

5. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $21.48 to $21.67. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did ALHC report for John E. Kao?

The report shows sales of Alignment Healthcare common stock associated with Chief Executive Officer and director John E. Kao on 01/12/2026, carried out through holdings in the JEK Trust, for which he serves as trustee.

How many Alignment Healthcare (ALHC) shares were sold and at what prices?

The JEK Trust sold 177,273 shares at a weighted-average price of $21.0997 per share and 2,727 shares at a weighted-average price of $21.5665 per share, with individual trades occurring within the stated price ranges.

How many ALHC shares does John E. Kao hold after these transactions?

After the reported sales, the filing shows 2,832,641 Alignment Healthcare common shares held indirectly through the JEK Trust and 1,568,379 shares held directly in John Kao’s name.

Were the ALHC insider sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on 03/12/2025, which is designed to provide an affirmative defense for prearranged trading.

What is the role of the JEK Trust in these ALHC share holdings?

The filing explains that the reported indirect holdings represent securities held by the JEK Trust, dated February 8, 2021, of which John E. Kao is the trustee. A separate footnote notes a prior transfer of 665,915 shares from his direct holdings to the trust on 01/08/2026.

What price ranges are disclosed for the ALHC stock sales?

The weighted-average prices reflect multiple trades. One set of sales occurred between $20.48 and $21.47 per share, and the other between $21.48 and $21.67 per share, with detailed breakdowns available on request as noted in the footnotes.